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Abstract: Sesquiterpene lactones, a vast range of terpenoids isolated from Asteraceae species, exhibit
a broad spectrum of biological effects and several of them are already commercially available, such as
artemisinin. Here the most recent and impactful results of in vivo, preclinical and clinical studies
involving a selection of ten sesquiterpene lactones (alantolactone, arglabin, costunolide, cynaropicrin,
helenalin, inuviscolide, lactucin, parthenolide, thapsigargin and tomentosin) are presented and discussed,
along with some of their derivatives. In the authors’ opinion, these compounds have been neglected
compared to others, although they could be of great use in developing important new pharmaceutical
products. The selected sesquiterpenes show promising anticancer and anti-inflammatory effects, acting
on various targets. Moreover, they exhibit antifungal, anxiolytic, analgesic, and antitrypanosomal
activities. Several studies discussed here clearly show the potential that some of them have in
combination therapy, as sensitizing agents to facilitate and enhance the action of drugs in clinical use.
The derivatives show greater pharmacological value since they have better pharmacokinetics, stability,
potency, and/or selectivity. All these natural terpenoids and their derivatives exhibit properties that
invite further research by the scientific community.
Keywords: Asteraceae; sesquiterpene lactones; alantolactone; arglabin; parthenolide; thapsigargin;
in vivo study; anticancer; anti-inflammatory
1. Introduction
Traditional or folk medicine relies heavily on the use of compounds-rich plants, like those of
the Asteraceae family, of which many such species are commercially available in the form of herbal
preparations. These are particularly rich in a wide range of natural terpenoids named sesquiterpene
lactones [1] that, in some cases, are considered the active principles of such therapeutic plants [2].
Structurally speaking, sesquiterpene lactones are terpenes that have in common a basic structure
of 15 carbons (thus the prefix sesqui-) resulting from biosynthesis involving three isoprene units
with a cyclical structure along with a fused α-methylene-γ-lactone ring [3]. Sesquiterpene synthases
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catalyze a common biosynthesis route for sesquiterpene lactones, based on the cyclization of farnesyl
phosphate resulting from the 2-C-methyl-D-erythritol-4-phosphate (MEP) and mevalonate (MVA)
pathways of dimethylalyl diphosphate and isopentenyl diphosphate precursors in chloroplasts and
cytosol, respectively [4]. However, sesquiterpene lactones have very different chemical structures
regarding the type and position of the substituents, as well as the size of the non-lactone ring [5,6].
For this reason, in structural terms, sesquiterpene lactones are organized into several subclasses:
eudesmanolide (a 6/6 bicyclic structure), guaianolide and pseudoguaianolide (both 5/7 bicyclic
compounds), germacranolide (with a 10-membered ring) and xanthanolide (containing a non-cyclic
carbon chain and a seven-membered ring) [7,8] (Figure 1).
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In terms of health promotion, the applications of sesquiterpene lactones and their derivatives
are a key research area. From this point of view, in vivo, preclinical and clinical studies are those that
allow a more realistic assessment of their medicinal potential [23].
The literature on this topic is extensive, especially for the most successful compounds; however,
studies on less known sesquiterpenes and their derivatives show that these compounds deserve more
attention, since they could play an important part in future human health maintenance. Therefore, this
review aims to point out the results of the most impactful and recent in vivo and (pre)clinical studies
of these insufficiently explored compounds and derivatives, which could be a valuable alternative in
the development of new therapeutic drugs.
2. Sesquiterpene Lactones with Significant In Vivo Activity
2.1. Alantolactone
The eudesmanolide alantolactone (1) (C15H20O2) (Figure 2) was first isolated from Inula helenium
L. roots, and later was also found in other Inula species [24], as well as non-Inula spp. such as
Saussurea lappa C.B. Clarke [25] and Aucklandia lappa DC. [26].
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although its total synthesis is possible [27,28]. Modern laboratory techniques have resulted in a 
significant increase in its extraction yield [29–31]. For example, ~3% pure alantolactone (1) yields were 
obtained from Inula helenium roots by Zhao et al. [30], which meant a significant improvement over 
the ~1% yields from the roots of Inula magnifica Lipsky [32]. 
Although alantolactone is associated with allergic contact dermatitis triggered by Inula species 
[33–35], this compound was first described as anti-helminthic [36], with subsequent studies 
demonstrating its tremendous potential, mainly as antitumor [37–40], anti-inflammatory [26,41], and 
antioxidant [42] agent. 
Regarding anticancer activity, the effect of alantolactone (1) on leukemia is well documented 
and was recently reviewed by Da Silva Castro et al. [43]. Xu et al. [44] reported a positive and 
significant effect (1) on B-cell acute lymphoblastic leukemia. In this study, 100 mg/kg (b.w.) doses 
were intravenously administered every two days in leukemia xenografted NOC/SCID mice. Results 
showed that treated mice lived an average of eight days more than non-treated mice (31.5 days after 
xenografting in treated compared to 23.5 days in non-treated mice), without significant weight loss. 
Before this study, Chun et al. [45] had also reported an in vivo antitumor effect on triple negative 
breast cancer in mice. The researchers used only a 2.5 mg/kg (b.w.) dose every two days to treat 
athymic nude mice xenografted with MDA-MB-231 cells. In this assay, alantolactone (1) reduced 
tumor size by over half, and significantly reduced tumor weight by about half after 24 days. 
Alantolactone (1) also exhibits in vivo activity against gastric cancer. Human gastric cancer cells 
(SGC-7901) were xenografted onto nude athymic mice, which were treated with 15 mg/kg (b.w.) of 
alantolactone (1) injected every two days [46]. Alantolactone (1) caused significant tumor growth 
inhibition and reduced Ki-67 and Bcl-2 expression (tumor associated proteins), without significant 
liver and kidney toxicity or impact on mouse weight [46]. 
Alantolactone (1) has also proven to be an especially potent sensitizing agent. In fact, it exhibits 
a synergistic effect with known chemotherapy drugs, such as oxaliplatin. Cao et al. [47] showed that 
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Alantolactone (1) is obtained mainly by extraction and purification from natural sources, although
its total synthesis is possible [27,28]. Modern laboratory techniques have resulted in a significant
increase in its extraction yield [29–31]. For example, ~3% pure alantolactone (1) yields were obtained
from Inula helenium roots by Zhao et al. [30], which meant a significant improvement over the ~1%
yields from the roots of Inula magnifica Lipsky [32].
Although alantolactone is associated with allergic contact dermatitis triggered by Inula
species [33–35], this compound was first described as anti-helminthic [36], with subsequent studies
demonstrating its tremendous potential, mainly as antitumor [37–40], anti-inflammatory [26,41],
and antioxidant [42] agent.
Regarding anticancer activity, the effect of alantolactone (1) on leukemia is well documented
and was recently reviewed by Da Silva Castro et al. [43]. Xu et al. [44] reported a positive and
significant effect (1) on B-cell acute lymphoblastic leukemia. In this study, 100 mg/kg (b.w.) doses
were intravenously administered every two days in leukemia xenografted NOC/SCID mice. Results
showed that treated mice lived an average of eight days more than non-treated mice (31.5 days after
xenografting in treated compared to 23.5 days in non-treated mice), without significant weight loss.
Before this study, Chun et al. [45] had also reported an in vivo antitumor effect on triple negative breast
cancer in mice. The researchers used only a 2.5 mg/kg (b.w.) dose every two days to treat athymic nude
mice xenografted with MDA-MB-231 cells. In this assay, alantolactone (1) reduced tumor size by over
half, and significantly reduced tumor weight by about half after 24 days. Alantolactone (1) also exhibits
in vivo activity against gastric cancer. Human gastric cancer cells (SGC-7901) were xenografted onto
nude athymic mice, which were treated with 15 mg/kg (b.w.) of alantolactone (1) injected every two
days [46]. Alantolactone (1) caused significant tumor growth inhibition and reduced Ki-67 and Bcl-2
expression (tumor associated proteins), without significant liver and kidney toxicity or impact on
mouse weight [46].
Alantolactone (1) has also proven to be an especially potent sensitizing agent. In fact, it exhibits a
synergistic effect with known chemotherapy drugs, such as oxaliplatin. Cao et al. [47] showed that a
10:2 mg/kg (b.w.) dose of alantolactone: oxaliplatin reduced tumor volume and weight by more than
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50% in athymic mice xenografted with colorectal tumor cells (HCT116). The anticancer effect increased
substantially when both compounds were used together, as opposed to alone. This result is in line
with that obtained by He et al. [48], according to which, using a small weekly injected dose of 3 mg/kg
(b.w.), tumor volume significantly decreased by around 75% in xenografted pancreatic cancer cells
(PANC-1), while increasing cancer cell chemosensitivity to oxaliplatin, revealing a synergistic action.
Alantolactone’s anticancer mechanism was also the main focus of several studies, some of them
mentioned in recent reviews [49,50] The authors attribute its activity to the multiple pathways it
activates. Alantolactone (1) acts as an alkylating agent leading to inhibition of key enzymes and proteins,
and as an apoptosis inducer in cancer cells at mitochondrial level by interacting with cytochrome
c. It promotes overproduction of reactive oxygen species (ROS) due to specific caspase activation,
by inhibiting autophagic deregulation, among other processes.
Beyond its anticancer activity, compound 1 also exhibits interesting anti-inflammatory activity.
Ren et al. [51] used the DSS-induced colitis mouse model to test alantolactone (1) anti-inflammatory
activity. A 50 mg/kg dose reversed colitis symptoms (bloody diarrhea, colon shortening and weight
loss), besides significantly reducing pro-inflammatory cytokine TNF-α expression (to about half that
of positive control) and IL-6 (by over 2.5 times compared to positive control) [51]. Wang et al. [41],
showed that a 10 mg/kg (b.w.) dose of alantolactone (1) significantly improved neurological function
and reduced cerebral edema in a traumatic brain injury mouse model. This neuroprotective effect was
attributed to alantolactone’s capacity to inhibit the NF-κB inflammatory pathway and the cytochrome
c/caspase-mediated apoptosis pathways [41]. To the best of our knowledge, no other authors have
elaborated on this interesting double action: the fact that alantolactone (1) can simultaneously activate
apoptotic pathways in cancer cells and inhibit these pathways in a cerebral edema model.
Seo et al. [52] described the neuroprotective effect of alantolactone (1) using amyloid β25–35-
induced ex vivo neuronal cell death and scopolamine-induced amnesia in mouse models meant to emulate
conditions common to neurodegenerative conditions like Alzheimer’s disease. A 1 µM alantolactone
(1) treatment increased cortical neuron viability to almost baseline control readings, and 1 mg/kg
(b.w.) significantly decreased scopolamine-induced cognitive impairments. It is a interesting to
note that this particular neuroprotective effect is attributed to a drop in ROS levels. High ROS
concentrations are associated with the neurodegenerative damage of Alzheimer’s disease. Again,
alantolactone (1) exhibits a double action: it raises ROS levels to induce apoptosis in murine models of
neurodegenerative damage.
The interesting advances with alantolactone (1) derivatives are also worth mentioning.
Kumar et al. [53] assayed three of the 17 thiol derivatives synthesized, at 10 mg/kg (b.w.) doses,
in mice showing that they have in vivo anti-inflammatory activity comparable to alantolactone (1).
The novel compounds shared alantolactone’s anti-inflammatory mechanisms. Another noteworthy
study involving alantolactone (1) derivatives was published in 2018 by Li et al. [54], testing 44 derivatives
for their ability to inhibit induced pulmonary fibrosis in mice. The results showed that 2 of these
compounds are particularly active at 100 mg/kg (b.w.), reducing the fibrotic area by more than 60%.
This is achieved by inhibition of the TGF-β1 pathway of myofibroblast differentiation. It should be
noted that no toxic effects were observed for either compound in the chronic toxicity test (seven days),
using a dose of 2 g/kg (b.w.) administered orally. Finally, a patent involving an alantolactone (1)
spiro-isoxazoline derivative was filed in June 2019 (US patent N◦ 20190185487) for the development
and production of these compounds that exhibit significant anti-inflammatory activity.
One factor which contributes to making alantolactone (1) very interesting as a future medicine is
its low toxicity. In work by Khan et al. [55], Kunming mice treated with 100 mg/kg (b.w.) alantolactone
(1) showed no significant signs of hepatotoxicity or nephrotoxicity, in line with the previously cited
work by He et al. [38]. This is especially important for alantolactone (1) as an anticancer drug, because
it is well known that the liver and kidneys are particularly susceptible to negative side effects from
chemotherapy approaches [56,57].
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Another engaging finding obtained by Khan et al. [55] is alantolactone’s ability to cross the
blood-brain barrier. It may thus become useful in the treatment of brain tumors or other conditions
involving the central nervous system (CNS), since the blood-brain barrier is the greatest obstacle for
drug delivery to those areas [58].
The metabolism and pharmacokinetics of alantolactone (1) have also been studied in vivo, with
future pre-clinical testing in mind. Research shows that alantolactone (1) exhibits low absorption and
is rapidly eliminated after intravenous and oral administration. Its metabolism involves conjugation
with thiol, and α, β-unsaturated carbonyl is the preferential structural metabolic site. The low aqueous
solubility of alantolactone (1) causes low oral bioavailability [59–61].
All these recent reports show there is great interest in alantolactone (1), and that it has potent
proven in vivo activities, mainly several different types of anticancer activity. This broad-spectrum
activity, combined with its synergistic action with known cancer therapy agents, shows alantolactone
(1) has great potential for future drug development. However, further research is necessary, especially
clinical trials, to identify its intracellular action sites and secondary targets and thereby elucidate its
mode of action.
2.2. Arglabin
Arglabin (2) (Figure 3), is a guaianolide sesquiterpene lactone with the chemical formula
C15H18O3, isolated from several species including Artemisia myriantha Wall. ex Besser [62,63],
Artemisia jacutica Drob [64], and Artemisia glabella Kar. and Kir. species [65] where the extraction yield
was 0.27% [66]. Fortunately, several synthetic and hemisynthetic methods for preparing compound 2
have been reported [66–70], allowing it to be provided in the quantities necessary for research and
medicinal applications.
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Figure 3. Structure of arglabin (2).
The arglabin (2) molecule contains a 5,7,5-tricyclic ring structure with contiguous stereo centers [70].
Furthermore, it contains both an epoxide and an α,β-unsaturated Michael acceptor, two functional
groups that have important roles in its pharmacological activities [71]. There are many research lines
advancing towards more effective drugs on the basis of the arglabin (2) molecule. New arglabin (2)
derivatives have been obtained by chemical modification, the most successful being obtained via
amination followed by treatment with gaseous hydrochloric acid. This converts arglabin (2) into the
hydrochloride salt of the dimethyl amino adduct, which is very soluble in water [66,72]. This arglabin
(2) salt form was used in the therapy of several cancer types such as breast, lung, liver and esophageal
tumors in oncological clinics of Kazakhstan [73–75]. Treatment of an esophageal carcinoma patient
with compound 2 contributed to a significant reduction in tumor volume, favoring its regression and a
lower incidence of leucopenia [75].
In terms of mechanism of action, arglabin (2) inhibits farnesyl protein transferase enzyme [65,72].
It influences DNA synthesis in murine P388 lymphocytic leukemia cells [74]. Recently, Schepetkin and
co-authors [76] have reported that compound 2 inhibits T-cell receptor activation and anti-CD3-induced
movement of intercellular Ca2+ ions ([Ca2+]i), blocks ERK1/2 phosphorylation and depletes [GSH] in
Jurkat T cells.
The anticancer effect of Arglabin (2) was also demonstrated by He and colleagues [77] on
xenografted oral squamous cell carcinomas. They elucidated that tumor growth is inhibited via
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downregulation of relevant protein expression in the mTOR/PI3K/Akt signaling pathway and
impairment of mitochondrial membrane potential, leading to apoptosis.
Recently, the pharmacokinetic properties of arglabin (2) have been reviewed [72], highlighting that
it mainly accumulates in the liver, quickly reaches peripheral tissues and penetrates the blood-brain
barrier. Furthermore, according to the literature, arglabin (2) has no described adverse effects, since
it does not affect normal liver and kidney function or cause local irritative/allergenic reactions, nor
mutagenic or embryotoxic effects [66,72,78].
Besides anticancer activity, arglabin (2) demonstrated in vivo anti-arthritis activity in a rat model.
Arglabin (2) lowers the levels of inflammatory mediators and cytokines, and reduces expression of
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), COX-2 (cyclooxygenase-2) and
iNOS (inducible nitric oxide synthase) [79]. Abderrazak and co-authors [80] suggest that arglabin (2) is
a compound with great potential in inflammation and atherosclerosis therapy. Using a high-fat diet
ApoE2.Ki mouse model, experimental results [80] showed that arglabin (2) reduces inflammation by
decreasing IL-1β and IL-18 levels and increases autophagy apoptosis [81].
Studies carried out with arglabin (2) show its potential for developing new anticancer and/or
anti-inflammatory drugs, the main limiting factor being its low bioavailability. The preparation of
soluble active versions of compound 2, and/or new delivery systems may attract further interest in this
sesquiterpene lactone.
2.3. Costunolide
Costunolide (3) (Figure 4), has the same chemical formula as alantolactone (1) (C15H20O2). It is
a member of the germacranolide subclass and was first isolated from Saussurea costus (Falc.) Lipsch.
roots in 1960 [82]. It is present in many Asteraceae genera such as Inula [24], Lactuca and Helianthus [83],
but also those from other families like Magnoliaceae [84].
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reduce the number of lung metastases to around one third of that in the control group. Western blot
analysis of the tissues revealed this effect could be attributed to costunolide (3) inhibition of STAT3
transcription, a factor that is widely kno n to be linked to oncogenesis and cancer proliferation [93].
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It is interesting to note the similarity between previously mentioned STAT3 inhibitory activity by
alantolactone (1) [45]. To highlight another similarity, costunolide (3) also exhibits activity against
gastric adenocarcinoma in xenografted mice [94]. Results from this study showed costunolide (3)
induced caspase-mediated mitochondrial apoptosis in cancer cells and a 50 mg/kg (b.w.) dose on
alternate days significantly reduced tumor size to about half. It achieved very similar results to
the positive control cisplatin, a chemotherapeutic agent used in clinical treatment [94]. Interesting
to note is costunolide’s anticancer effect through telomerase reverse transcriptase inhibition [95], a
mechanism not known in alantolactone (1). As reported by the researchers, a 5 mg/kg (b.w.) dose
injected on alternate days in glioma xenografted mice significantly reduced tumor size by over
50%. This inhibition was associated with reduced telomerase activity, which leads to ROS-associated
apoptosis [95]. A subsequent work by the same research group also showed the same dose affects lipid
metabolism in glioma xenograft tumors, by lowering expression of FASN, SREBP-1, and PGC-1α [96],
which are key genes targeted for cancer treatment [97–99].
Beyond costunolide’s anticancer effect, it has also proven to be a potent anti-inflammatory
agent [90], as well as an antidiabetic, antihelminth, antimicrobial, antiulcer and antioxidant [91].
Its anti-inflammatory action has been well documented in vitro [84,100] and in vivo, appearing to be
linked to NF-κB pathway inhibition [101]. For example, costunolide (3) is able to suppress inflammatory
angiogenesis [102], alleviating gastric ulcers [103], and acute lung and liver damage [104–107].
Recently, studies have shown that costunolide (3) also exhibited anti-osteoarthritic effects [108].
In fact, treatment in rats with osteoarthritis causes attenuation of cartilage degeneration compared to
the control osteoarthritic group. The observed effect has been attributed to the inhibitory action of
this compound on the Wnt/β-catenin and NF-κB signaling pathways, and on the expression of matrix
metalloproteinases [108].
Costunolide (3) seems to be also a powerful antiasthmatic [109]. In this work, the researchers
treated asthma-induced mice with 10 mg/kg (b.w.) before an immune challenge. Results showed
a 61.8% inhibition of asthma-associated eosinophil increase, as well as significantly reducing lung
inflammation scores and mucin production [109].
Recently, it has been shown that costunolide (3) is an effective inducer of hair growth in mice [110].
For this assay, the researchers implanted mouse dermal cells, treated with 3 mM costunolide (3) for
two days. Results showed a 2.5-fold increase in induced hair follicles in the implanted treated cells,
and topically applied costunolide (3) significantly and visibly improved hair growth. The authors
claim this might be due to activation by compound 3 of key follicle-cell cycle pathways, including the
Wnt/b-catenin, Shh/Gli, and TGF-β/Smad pathways. It is worth mentioning the TGF-β/Smad pathway
was also mentioned in previous studies related to anti-inflammatory action of costunolide (3) [106].
Costunolide (3) derivatives have also proven to be highly interesting, with remarkable in vivo
effects. In recent work by Cala et al. in an agro-research context [111], many different functional groups
were added to the sesquiterpene backbone, yielding, among others, two amino and two methyl ether
derivatives with strong herbicidal activity. The etiolated wheat coleoptile assay indicated treatment
with these costunolide (3) derivatives had dose-dependent growth inhibition responses equivalent to
a widely used synthetic herbicide used as positive control. These results show there is potential for
some of these derivatives as bio-herbicides, but further studies are necessary. There was also another
interesting result of this work which the authors did not address, but is worth pointing out: two tested
thiol derivatives boosted coleoptile growth instead of inhibiting it, with one compound increasing
coleoptile length by ~30% with a 30 µM treatment. The general implication of these results is that
costunolide (3) modification can be powerful and versatile, capable of yielding diametrically opposed
bioactive compounds depending on the functional group added.
In conclusion, costunolide (3) is a highly multitalented and potent bioactive compound. Similar to
other sesquiterpene lactones such as the previously discussed alantolactone (1), much of its potential
for future drug development lies in its anticancer and anti-inflammatory effects. It is interesting that
there appears to be more work done with costunolide (3) derivatives than alantolactone (1) derivatives,
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which in general suggests greater interest of the scientific community in costunolide (3) as opposed to
alantolactone (1). With so many relevant publications in 2019 alone, we expect to see costunolide (3)
research ramping up to a pre-clinical stage very soon.
2.4. Cynaropicrin
Cynaropicrin (4) (Figure 5) is a guaianolide type sesquiterpene lactone with a chemical formula of
C19H22O6 and a 5,7,5 fused tricyclic skeleton [112].
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for the first ti e [113] and later it as found in Cynara cardunculus L. [114,115] and Cynara scolymus
L. species [116], being considered as a che otaxono ic arker for artichoke plant species [112].
Cynaropicrin (4) as also found in any species of steraceae fa ily such as Centaurea drabifolia
subsp. floccosa (Boiss.) Wagenitz and Greuter [117], Psephellus sibiricus (L.) Wagenitz [118], Rhaponticum
pulchrum Fisch. and C.A.Mey. [119], Moquinia kingii (H.Rob.) Gamerro [120], Saussurea calcicola
Nakai [121], Saussurea costus (Falc.) Lipsch. [122,123], Tricholepis glaberrima DC. [124], and many
others [112]. Yields of cynaropicrin (4) extraction from Cynara cardunculus L. leaves using ethanol, ethyl
acetate, dichloromethane and water were 56.9, 37.5, 40.3 and 13.6 mg/g dry weight, respectively [125].
The biological activities of cynaropicrin (4), as with other sesquiterpenic lactones, are related to
its pharmacophore γ-butyrolactone ring [112]. There are many studies reporting on the important
pharmacological activities of cynaropicrin (4), and plants rich in cynaropicrin (4), such as antitumor,
anti-inflammatory, antitrypanosomal, and antihepatitis C virus, among many others. Due to these
notable effects, cynaropicrin (4) will be suitable for the development of medicinal compounds [123].
Cynaropicrin (4) is the first natural product that in vivo potently inhibits the African trypanosome
diseases [126]. Using the acute model of mice infected with Trypanosoma brucei rhodesiense STIB 900,
when treated with two doses of 10 mg/kg (b.p.) per day, on the 7th day after infection, there was a 92%
reduction in parasitemia when compared to the untreated group. Additionally, selectivity indices of
7.8 were obtained for cynaropicrin (4) against L6 cells of rat myoblasts [127]. The action mechanism
is still under study to date, but is thought to be related to the interaction of compound 4 with the
trypanothione redox system in Trypanosoma brucei [127]. However, Da Silva et al. [128] demonstrated
that cynaropicrin (4) at a dose of up to 50 mg/kg (b.w.) per day has no effect in mice infected with
Trypanosoma cruzi, in either Y or Colombiana strains. The synthesis and semi-synthesis of several
cynaropicrin (4) derivatives allowed the structure/antitrypanosomal activity of these compounds to be
evaluated. It was concluded that the α-methylene-γ-lactone structure is indispensable to maintain
the biological effect, whereas 3-OH and 19-OH derivatization does not change the activity and some
types of side-chain promote the selectivity of the compound [129,130]. The in vivo evaluation of
some derivatives, using the Trypanosoma brucei rhodesiense acute mouse model, indicated that the
dimethylamino derivative exhibits much less toxicity than cynaropicrin (4), but also less activity [129].
Cynaropicrin (4) also showed the ability in vivo to delay the effects of skin photoaging, promoting
the proliferation of melanocytes and keratinocytes, by acting as inhibitor of NF-kB transcription
activity [131].
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2.5. Helenalin
Helenalin (5) (C15H18O4) (Figure 6), a 5/7-fused bicyclic sesquiterpene lactone that belongs to the
pseudoguaianolide subclass. It is very abundant in Arnica montana L. but is also identified in other
species from Arnica and Helenium genera and from Centipeda minima (L.) A.Braun and Asch. [132–136].
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DNA-binding [143], inhibiting neutrophil chemotaxis and migration as well as 5-lipoxygenase and 
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Experiments performed by Schröder et al. [145] demonstrate that compound 5 inhibits platelet 
aggregation induced by collagen, 5-hydroxytryptamine secretion and thromboxane formation, 
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function via interaction with platelet sulfhydryl groups in a way most likely associated with reduced 
phospholipase A2 activity. 
Helenalin (5) inhibited complete Freund’s adjuvant-induced arthritis and carrageenan-induced 
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Alcohol extracts containing helenalin (5) and its derivatives have been used as a staple of
traditional herbal anti-inflammatory medicine for many decades [134]. For instance Arnica montana L.
solutions are used to treat rheumatism, arthritis, inflammation, hematoma, soreness, sprains, swelling
and muscle spasms from athletic activity etc., seasonally triggered arthritis, arteriosclerosis, angina
pectoris, postoperative conditions, and joint pain. The plant is used externally in creams, alcoholic
tincture, and ointment form but also taken highly diluted in homeopathic remedies [134]. Many such
preparations, even hair oil and shampoo, are commercially available from a range of suppliers in
healthfood shops and pharmacies almost worldwide [137]. Likewise, clinical trials have aimed to
assess topical Arnica applications, regarding possible reduction of laser-induced minor hematomas
and osteoarthritis-type symptoms. Orally administered homeopathic formulations are also widely
employed in the clinical setting to treat and manage conditions such as carpal tunnel, slow knee-surgery
recovery, tonsil and wisdom tooth extractions, facelifts, neuralgia, hysterectomy, venous surgery, hallux
valgus, heart-valve surgery, hemarthrosis, prolonged intravenous perfusion, joint sprains and strains,
muscle pain, etc. [133].
Helenalin (5) inhibits NF-κB transcription of inflammatory cytokines, which have an essential
role in both inflammation and cancer [138]. It also efficiently inhibits cancer cell proliferation through
a variety of action modes, e.g., telomerase inhibition [139], DNA and protein synthesis attenuation,
apoptosis induction and promoting reactive oxygen species generation [140]. It is noteworthy that
inhibition of NF-κB activation associated with another sesquiterpene, helenin, occurs in T-cells, B-cells
and epithelial cells in response to four different stimuli, nullifying kB-driven gene expression. Since this
activity does not affect transcription factors Oct-1, TBP, Sp1 or STAT 5, this NF-κB activation is probably
inhibited selectively [141,142]. Lyss et al. [141] described how helenalin modifies the NF-κB/IκB complex,
preventing IκB release. They proposed a molecular action mode for the anti-inflammatory influence,
which is different from other nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and
indomethacin. Furthermore, it targets Cys38 on p65, ablating DNA-binding [143], inhibiting neutrophil
chemotaxis and migration as well as 5-lipoxygenase and leukotriene C4 synthase activities [144].
Experiments performed by Schröder et al. [145] demonstrate that compound 5 inhibits platelet
aggregation induced by collagen, 5-hydroxytryptamine secretion and thromboxane formation,
depending its on concentration (between 3–300 µM). They concluded that helenalin inhibits platelet
function via interaction with platelet sulfhydryl groups in a way most likely associated with reduced
phospholipase A2 activity.
Helenalin (5) inhibited complete Freund’s adjuvant-induced arthritis and carrageenan-induced
paw edema in the rat [146]. Topical application of Arnica 3D gel (10%), combined with a 10 mA
microcurrent for 2 min also significantly improved wound healing in a linear incision wound model
in the rat back [147]. The evidence was consistent with a higher percentage of mature collagen
fibers and a significantly larger total number of cells in the wound, as assessed by structural and
morphometric analysis. According to this, different proportions of Arnica montana extracts alone or
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combined with other plants have been patented for their therapeutic potential [137]. Widrig et al. [148]
performed a randomized, double-blind study in 204 patients with osteoarthritis (OA) to compare
the effects of ibuprofen (5%) and Arnica montana gel (50 g tincture/100 g) containing helenalin
(5), 11α,13-dihydrohelenalin and its ester. The results show that short-term use, up to three weeks,
of Arnica gel improves pain and hand function in OA, indistinguishably from ibuprofen gel. Substantial
antiosteoarthritic activity by blocking transcription factors NF-κB and NF-AT is attributable to helenalin
and derivatives.
Boulanger et al. [149] demonstrated that helenalin (5), intraperitoneally delivered at 20 mg/kg in
lactating-Balb/C mice 9 and 3 h prior to infection, reduced intracellular growth of Staphylococcus aureus
in mouse mammary glands This suggests the compound interferes with host molecular mechanisms
and not directly with Staphylococcus aureus growth. The authors conclude helenalin might be worth
investigating as a potential treatment for Staphylococcus aureus-induced mastitis in bovine species.
There is however some concern regarding this treatment, mainly regarding helenin persistence in the
animal’s milk, and whether or not the therapeutic doses pose short- and long-term toxicity risks. It is
therefore imperative to further study and characterize its safety and pharmacological properties.
Valan et al. [150] showed that helenalin (5) has a significant biphasic positive inotropic effect
on the myocardium of guinea pigs at doses of 10−5–10−3 mol. Nevertheless, concentrations above
10−3 mol. cause an irreversible negative inotropic action leading to a blocking of muscle contraction.
The skin is susceptible to environmental damage by multiple agents, particularly solar ultraviolet
(UV), which induces skin hyperpigmentation disorders. Expression of heat shock proteins (HSPs,
particularly HSP70) is receiving consideration in the field of cosmetics, to reduce skin damage and
signs of aging. Usui et al. [151] isolated AM-2 (helenalin 2-methylbutyrate) from Arnica montana as a
good inductor of HSP70, with low cytotoxicity. Treatment of cultured mouse melanoma cells with
AM-2 or Arnica montana extract up-regulated the expression of HSP70 in a dose-dependent manner.
It also activated the transcription factor for hsp genes, i.e., heat shock factor-1. They concluded
that both Arnica montana extract and AM-2 are likely to show beneficial effects if incorporated in
hypopigmenting cosmetics.
Acute liver injury is a life-threatening syndrome frequently associated with hepatocyte damage and
characterized by oxidative and inflammatory responses. Li et al. [136] recently observed that intragastric
administration of helenalin (5) for 10 days significantly ameliorated hepatic injury induced previously
in mice with LPS/D-GalN. These results were evidenced by the attenuation of histopathological changes
and the decrease in serum aminotransferase and total bilirubin activities. Therefore, helenalin (5) shows
a hepatoprotective effect against damage induced by LPS/D-GalN. This in turn may be associated with
reduced hepatocyte apoptosis, by protection of mitochondrial function and oxidative stress inhibition
by Nrf2 pathway activation, as well as attenuating inflammation by inhibiting NF-κB activation.
The co-authors of that study [152] submitted Patent No. CN 110283151 in 2019 as a method for isolation
of helenalin from Centipeda minima and its application for treating hepatic fibrosis and inflammation.
Furthermore, the same authors [153] patented it for inhibiting hepatic stellate cell activation, showing
the advantages of reducing collagen deposition and synthesis of inflammation-related proteins,
promoting death of stellate cells, and its application in liver fibrosis treatment.
2.6. Inuviscolide
The guaianoline-type sesquiterpene lactone inuviscolide (6) (C15H20O3) (Figure 7) was identified
in Ferula communis (Apiaceae) and described to be the main metabolite in Inula viscosa (L.) Ait. [154].
Inuviscolide (6) inhibited in vivo inflammation in mice, as shown in the investigation performed
by Hernández et al. [155]. The authors used inuviscolide (6) and ilicic acid from Inula viscosa and found
that compound 6 influenced cell degranulation and leukotriene biosynthesis, as well as neurogenic
drive and glucocorticoid-like interactions. During the testing, ear and paw edema were induced
in Swiss female mice using phorbol esters or ethyl phenylpropiolate (EPP), and phospholipase A2
(PLA2) or serotonin, respectively. The drug dose was applied topically in the ear models but as
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subcutaneous or intraperitoneal injections in the paw models. For quantitation of leukotriene B4
(LTB4) formation, high-performance liquid chromatography (HPLC) was performed on rat peritoneal
neutrophils. The results showed that compound 6 reduced PLA2-induced edema with an ID50 of
98 µmol/kg. The results did not indicate that glucocorticoid response modifiers had an influence on
the edema induced by serotonin. In intact cells, inuviscolide (6) resulted in reduced generation of
LTB4 (IC50 value of 94 µM). The overall results indicated that compound 6 has an important role in the
anti-inflammatory activity of Inula viscosa, being more active than ilicic acid. The action mechanism was
suggested to be related to an interference with leukotriene synthesis and to PLA2-induced mastocyte
release of inflammatory mediators [156].
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2.7. Lactucin and Its Derivatives Lactupicrin, and Lactucopicrin
Other compounds from the guaianolide subclass are lactucin (7) (C15H16O5) and its 8- and 15-
(4-hydroxyphenylacetate) derivatives lactupicrin (8) and lactucopicrin (9), respectively (Figure 8).
Dolejš et al. [156] and Ruban et al. [157] had previously described the chemical structure of lactucin (7).
These compounds are distributed within Asteraceae like Lactuca serriola [158], especially plants commonly
used in salads. Lactuca sativa (lettuce), Cichorium intybus (chicory and radicchio), and Cichorium endivia
(endive) have been reported to contain lactucin (7) and lactucin-related substances [159–164]. The content
depends largely on the species, variety and the part of the plant analyzed. In fact, lettuce guaianolide
content was high and reached concentrations between 61.7 mg/mL and 147.1 mg/mL in its latex [160]
and 2.9 mg/g to 36.1 mg/g in the overall plant, expressed as dry weight [162].
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The biological activities of lactucin (7) and lactucin-related compounds had already attracted
interest at the end of the 19 h century, as they were credited to be responsible for the bitter taste and
pharmacological effect of lactucarium or lettuce opium [165]. This is the condensed latex of wild
lettuce Lactuca virosa. This dried exudate was used in Europe for centuries with similar applications to
opium as an analgesic, antitussive, and sedative [163]. Due to its widespread use, it was described
and standardized in the United States Pharmacopoeia (USP) and the British Pharmaceutical Codex as
a sedative for irritable cough and as a mild hypnotic for insomnia [166–168]. Lactucopicrin (9) and
lactucin (7) were identified as its major active compounds, although compound 7 was suggested to be
one of the main metabolites related to the sedative and the sleep-promoting effects [163]. In an in vivo
study in mice, both substances were confirmed to be analgesics, with an activity equal to or greater
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than ibuprofen. In addition, when lactucin (7) and lactucopicrin (9) were administered to mice on the
hot plate, both compounds were revealed to have analgesic and sedative effects at concentrations of
15 and 30 mg/kg, respectively. Furthermore, in a spontaneous locomotor activity test, these compounds
were active at concentrations of 30 mg/kg [168].
Although the pure compounds currently are not easily available on the market, several lettuce
extracts and seed oils containing these sesquiterpene lactones as main active compounds are
commercialized, e.g., Sedan® (Pharco Pharmaceutical Company, Egypt). The sedative effects were
addressed in the pilot study by Yakoot et al. [169]. The authors investigated if lettuce seed oil was
efficient and safe to treat patients with sleep disorders. The results showed that the seed oil of L. sativa
was a potentially hazard-free agent, able to reduce sleeping difficulties and alleviate mild to moderate
forms of anxiety in geriatric patients, without showing side effects [169,170]. Additionally, the study
performed by Kim et al. [163] examined the sleep-inducing and sleep-prolonging effect of four lettuce
varieties. The seed and leaf extracts were evaluated using a four-week-old ICR mouse model to analyze
their effects on pentobarbital-induced sleep. The results showed that both extract types lengthened
sleep duration and significantly reduced sleep latency at both evaluated doses of 80 mg/kg and of
160 mg/kg [163]. Although these studies in patients were performed with plant extracts reported to
contain lactucin (7) and its derivatives as principal active pharmacological compounds, they confirm
that their application for treatment of anxiety and sleep disorders is worthy of further evaluation.
Additionally, the results showed that these sesquiterpenes might be assessed as potential alternatives to
currently used sleep-promoting, sedative, and anxiolytic agents, with their varied negative side-effects
and addiction-potential.
2.8. Parthenolide
Parthenolide (10) (Figure 9) has the same chemical formula as inuviscolide (6) (C15H20O3) and is
the best known sesquiterpene lactone in the germacranolide class. It was isolated for the first time from
feverfew leaves and flowerheads (Tanacetum parthenium (L.) (Sch.Bip.), a plant known in traditional
Chinese medicine for centuries to treat various ailments. Among them, it is used to relieve fever, pain
of different etiologies such as migraine and rheumatoid arthritis and even to treat insect bites [171].
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NF-κB [182,183], as well as the proapoptotic activation of p53, along with reduced glutathione (GSH)
depletion [184]. Parthenolide rapidly induces ROS generation [185,186], and lowers histone deacetylase
activity (HDAC) [187] and DNA methyltranspherase 1 (DNMT1) [188]. Additionally, parthenolide can
interfere with microtubule function through tubulin binding [189].
Recent advances regarding in vivo therapeutic applications of parthenolide (10), mainly focused
but not limited to anticancer and anti-inflammatory activities, are discussed below, together with the
synergistic effects and toxicity of compound 10 and some derivatives.
One of the advantages of parthenolide (10) is its cancer stem-cell selectivity while remaining
non-cytotoxic to non-tumor cells [190,191]. In this case, the molecular mechanism of parthenolide
involves induction of apoptosis through mitochondrial and caspase signaling pathways, and also an
increase in the cytosolic concentration of calcium, cell cycle arrest, and inhibition of metastasis [178,192].
Cholangiocarcinoma (CC) is an intrahepatic bile duct carcinoma with a poor prognosis due to
being chemoresistant. Parthenolide induced oxidative stress-mediated apoptosis in CC cells and the
Bcl-2-related family of proteins modulated that susceptibility [193]. Moreover, intraperitoneal injection
of parthenolide at 4 mg/kg caused significant inhibition of tumor growth and angiogenesis in the
xenograft model [194]. Recently, Yun et al. [195] demonstrated that low concentrations of parthenolide
(5–10 µM) suppressed HO-1 expression, enhancing oxidative stress by the PKC-α inhibitor Ro317549
(Ro) through inhibition of Nrf2 expression and its nuclear translocation. The effects of parthenolide
(10) and Ro at 2.5 mg/kg on tumor growth were tested using a xenograft nude mouse tumor model
with subcutaneously implanted ChoiCK and SCK cells. This assay indicated that their combined
application more effectively inhibited cancer cell growth inhibition as compared to treatment with either
compound by itself. Furthermore, the effect of parthenolide on the development of colitis-associated
colon cancer (CAC) was investigated using a murine model of azoxymethane (AOM)/dextran sulfate
sodium (DSS) induced CAC. This study showed that parthenolide administration (10) at 2 and
4 mg/kg can significantly inhibit the inflammation-carcinoma sequence and be crucial in experimental
CAC regulation. The mechanism of action involves decreased NF-κB p65 expression levels blocking
phosphorylation and subsequent degradation of κB-α inhibitor (IκBα) [196]. The authors conclude
that parthenolide (10) could be a novel chemopreventive agent for CAC treatment [196].
Oral cancer is one of the five most common cancers worldwide. Chemoprevention is a new
approach to cancer research, focusing more on the prevention, suppression, and reversal of the
carcinogenic process by the use of natural plant products and/or synthetic chemical compounds.
Thus, Baskaran et al. [197] tested the chemopreventive potential of parthenolide in DMBA-induced
hamster buccal pouch carcinogenesis (DMBA, 7,12-dimethylbenz[a]anthracene). Oral administration
of parthenolide (10) at 2 mg/kg b.w. completely prevented tumor formation and significantly reduced
the nefarious histopathological changes. In addition, the parthenolide treated group showed significant
improvement regarding antioxidants, detoxification enzymes and lipid peroxidation.
Glioblastoma, or glioblastoma multiforme (GBM), is the most aggressive type of brain cancer
and is very difficult to treat. Nakabayashi and Shimizu [198] examined the effect of compound 10
on tumor growth using a xenograft mouse model of glioblastoma, administering it intraperitoneally
(10 mg/kg/day) for 22 days. It significantly inhibited the growth of transplanted glioblastoma cells
with respect to the control group.
Zhang et al. [199] demonstrated that a high parthenolide dose (8 mg/kg/day) impedes initiation
of experimental autoimmune neuritis (EAN), an animal model for peripheral nervous system acute
inflammatory disease. This is achieved by parthenolide suppressing TNF-α, IFN-γ, IL-1β and IL-17
pathways and quickly decreasing Th1 and Th17 cells in the early stages. Although this anti-inflammatory
effect is short-lived, compound 10 also suppresses late-stage recovery of EAN models, along with
inhibiting the apoptosis of inflammatory cells. Such results suggest that parthenolide is not suitable
for nervous system autoimmune disease treatment.
Nitric oxide (NO) plays a key role in the etiopathology of central nervous system (CNS) diseases
like multiple sclerosis (MS). It has been proposed that inhibition of NO synthesis could prove a relevant
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mechanism of action in treating multiple sclerosis and migraine. Accordingly, Fiebich et al. [200]
investigated the effect of parthenolide (10) on iNOS synthesis and NO release using primary rat
microglia. The results indicated that compound 10 prevents iNOS/NO synthesis and inhibits the
activation of p42/44 mitogen-activated protein kinase (MAPK), but not IkBα degradation or NF-kB p65
activation. These results show parthenolide may be a potential therapeutic agent in the treatment of
CNS diseases.
Mechanisms of axon regeneration and optimal functional recovery after nerve injury are key
to in higher animals. However, insufficient growth rates of injured axons often lead to incomplete
peripheral nerve regeneration. Gobrecht et al. [201], demonstrated that a single parthenolide injection
at 5 nM into the injured sciatic nerve or its systemic intraperitoneal application was already enough to
significantly increase the number and length of regenerating axons in the distal nerve at three days
post-lesion. This application of parthenolide (10) appears to act on the great instability of microtubules
in promoting axonal growth, at least in the CNS [174]. For this reason, the efficacy of parthenolide is
very promising for a therapeutic promotion of nerve regeneration, since compound application and
recurrent treatments are facilitated, compared to invasive local nerve injections [202].
Pulmonary fibrosis (PF) in general and idiopathic pulmonary fibrosis (IPF) in particular, is a
disease for which there is no effective therapy. In vivo studies have shown that parthenolide (10),
via intragastric administration, inhibited the NF-κB/Snail pathway, attenuating bleomycin-induced
pulmonary fibrosis. Moreover, there were significant improvements in body weight and other
pathological changes associated with this disease [203].
NF-κB has been associated with the cardiovascular system; in fact, its function is related to the
protection of cardiovascular tissues against injuries. However, its activation can also contribute to
tissue pathogenesis, depending on the type of cells in which it is activated [204]. It is known that
myocardial infarct size could be reduced up to 60% by antagonizing NF-κB activity [205]. To achieve
this, parthenolide (10) at 250 or 500 mg/kg (b.w.) was administered intraperitoneally before reperfusion
in rats, and caused a significant improvement in myocardial injury, with a reduction in the oxidative
and inflammation state, consequently reducing infarct size [206]. However, Tsai et al. [207] reported
that a prolonged treatment in bEND.3 cells affected Ca2þ signaling in the endothelial cells that regulate
vascular tone; therefore, care should be taken on using this compound in experimental designs
and clinically.
Parthenolide (10) has relatively poor pharmacological properties, derived from its low solubility
in water and consequently reduced bioavailability, which limit its potential clinical use as anticancer
drug. To increase its solubility, a series of parthenolide derivatives were obtained by diastereoselective
addition of several primary and secondary amines to the exocyclic double bond [208,209]. N,N-
Dimethylaminoparthenolide (DMAPT) (11) (Figure 9) was selected as a leader compound according to
its pharmacokinetic, pharmacodynamic and bioavailability properties [209,210]. When formulated as
a fumarate salt, DMPAPT is 1000-fold more soluble in water than parthenolide and maintained the
anticancer activity because, DMAPT (11) is rapidly converted back to parthenolide in body fluids (10).
Recently, molecular studies indicate that DMAPT has a similar action to parthenolide [192,211–213].
DMAPT has approximately 70% oral bioavailability and induces rapid death of primary human
leukemia stem cells (LSCs) from both myeloid and lymphoid leukemias and is highly cytotoxic to bulk
leukemic cell populations. Pharmacological studies carried out by Guzman et al. [210] using both mouse
xenograft models and spontaneous acute canine leukemias demonstrate in vivo bioactivity. Indeed,
DMAPT eliminates human AML stem and progenitor cells without harm to normal hematopoietic stem
and progenitor cells, and eradicates phenotypically primitive blast-crisis chronic myeloid leukemia
(bcCML) and acute lymphoblastic leukemia (ALL) cells. Moreover, it inhibited metastasis in a mouse
xenograft model of breast cancer and enhanced the survival of treated mice [210].
DMAPT was assayed in a phase I trial against acute myeloid leukemia (AML), acute lymphoblastic
leukemia (ALL) and other blood and lymph node cancers [12,176]. However, a year later the clinical
trials were suspended [214].
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Radiotherapy is widely used in cancer treatment; however, the benefits can be reduced by
radiation-induced damage to neighboring healthy tissues. Morel et al. [215] demonstrated in mice
that DMAPT (11) selectively induces radio-sensitivity in prostate cancer cell-lines, while protecting
primary prostate epithelial cell lines from radiation-induced damage. Compound 11 has the advantage
of being well-tolerated orally without the need to adjust the administration time to radiation exposure.
Radiation-induced lung fibrosis is considered a critical determinant for late normal tissue complications.
Therefore, the same group [216] examined the radioprotective effect of DMAPT (11) on fibrosis in
normal tissues, according to the image-guided fractionated radiotherapy protocols used clinically.
The results obtained show that DMAPT reduced radiation-induced fibrosis in the corpus cavernosum
of the rat penis (98.1%) and in the muscle layer around the bladder (80.1%), and also the tendency
towards reduced collagen infiltration into the submucosal and muscle layers in the rectum. They
concluded that DMAPT could be useful in providing protection from the radiation-induced side effects
such as impotence and infertility, urinary incontinence and fecal urgency resulting from prostate cancer
radiotherapy [216].
On the other hand, radiation-resistant prostate cancer cells often overexpress the transcription
factor NFκB. Mendonca et al. [217] suggest that DMAPT might have a potential clinical role as
radio-sensitizing agent in prostate cancer treatment. This conclusion is based on the finding that
combined treatment of PC-3 prostate tumor xenografts with oral DMAPT and radiation therapy
significantly reduced tumor growth, when compared to those treated with either DMAPT or radiation
therapy alone.
Li et al. [218], obtained a novel parthenolide derivative, HMPPPT, a 13-substituted derivative
((3R,3aS,9aR,10aR,10bS,E)-3-((4-(6-hydroxy-2-methylpyrimidin-4-yl)piperidin-1-yl)methyl)-6,9a-dimethyl-
3a,4,5,8,9,9a,10a,10b-octahydrooxireno [2′,3′:9,10]cyclodeca[1,2-b]furan-2(3H)-one) (12) (Figure 9),
with better bioavailability and pharmacological properties than DMAPT. In vitro studies pointed to
compound 12 as the most promising derivative, from safety profile and ADME property standpoints.
The newly identified compound was shown to have pro-oxidant activity and in silico molecular
docking studies with components of the NF-κB pathway also supporting a pro-drug mode of action.
This mechanism included release of parthenolide and covalent interaction with one or more proteins
involved in that pathway [218]. The in vivo oral bioavailability study of compound 12 in murine
PK at 10 mg/kg indicated that it has advantageous pharmacological properties and therefore can
be considered an agent to be considered in therapy against drug resistant chronic lymphocytic
leukemia [218].
In the last few years, nanotechnology has provided many selective strategies for the detection
and treatment of cancer, overcoming the problems associated with conservative cancer diagnosis and
therapy. In this context, the development and testing of parthenolide (10) nanoencapsulation and
derivatives is a way to enhance its potential to provide effective pharmaceutical products for clinical
use and resolve drawbacks such as low bioavailability [219–222]. Accordingly, several patents for
elaboration of parthenolide and its derivatives in nanocarriers, and various pharmaceutical preparations
combined with other products, have been recently registered in China: patents N◦ CN 110292640, 2019;
N◦ CN108721276, 2018; N◦ CN1087211330, 2018; N◦ CN106366068, 2017; N◦ CN 109276553, 2017.
In recent years, parthenolide has been suggested for use in combination therapy with other
anticancer agents, to overcome obstacles in the treatment of cancer, such as a) different types of cancer
cells, b) resistance to chemotherapy, and c) drug toxicity to normal cells.
TRAIL (tumor necrosis factor (TNF)-related apoptosis inducing ligand) is now being developed
as a promising natural immunity-stimulating molecule for clinical trials in cancer patients. However,
various malignant tumors are currently resistant. Kim et al. [223] investigated how parthenolide (10)
sensitizes colorectal cancer (CRC) cells to TRAIL-induced apoptosis. For this, HT-29 (TRAIL-resistant)
and HCT116 (TRAIL-sensitive) cells were treated with compound 10 and/or TRAIL. The results revealed
that parthenolide (10) increases induced apoptosis and upregulates DR5 protein level and surface
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expression in both cell lines, suggesting that combined therapy with TRAIL is a good strategy to
overcome the resistance of certain CRC cells.
Pancreatic cancer is a common malignancy with high occurrence worldwide, and a poor
survival rate. Recent research indicates that combination therapy with DMAPT (11) can enhance
the antiproliferative effects of gemcitabine in pancreatic cancer cells in vitro and in vivo [224].
Yip-Schneider et al. [225] showed that celecoxib (a cyclooxygenase 2 (COX-2) inhibitor) at 50 mg/kg/day
combined with DMPTA at 40 mg/kg/da has a significant inhibitory effect on tumor invasion of adjacent
organs and metastasis in pancreatic cancer induced in Syrian golden hamsters. It reduced NFκB activity,
and expression of prostaglandin E2 and its metabolite. They also demonstrated that compound 11
(40 mg/kg/day) in combination with sulindac (20 mg/kg/day) and gemcitabine (50 mg/kg twice weekly)
can delay or prevent progression of premalignant pancreatic lesions) in a genetically engineered mouse
model of pancreatic cancer [226]. Likewise, they demonstrated that DMAPT (11) (40 mg/kg/day) with
gemcitabine (50 mg/kg/day) considerably improved average survival, lowering the frequency and
multiplicity of pancreatic adenocarcinomas. This combination also significantly reduced tumor size
and the incidence of metastasis into the liver [227].
Parthenolide exerted a cytotoxic effect on MDA-MB231 cells, a triple-negative breast cancer
(TNBC) cell-line, however its success is scarce at low doses. In order to overcome this difficulty,
Carlisi et al. [228] tested a histone deacetylase inhibitor, SAHA (suberoylanilide hydroxamic acid),
which synergistically sensitized MDA-MB231 cells to the cytotoxic effect of parthenolide (10). It is
noteworthy that treatment with parthenolide alone increased the survival of cell pathway Akt/mTOR
and the consequent nuclear translocation of Nrf2, a protein regulating the expression of antioxidant
proteins that protect against the oxidative damage triggered by injury and inflammation, while
treatment with SAHA alone activated autophagy.
A phase 2 clinical trial indicated that actinomycin-D (ActD), a polypeptide antibiotic that
intercalates to DNA and inhibits mRNA transcription in mammalian cells, could be a potent drug
against pancreatic cancer. However, it is not a good candidate due to toxicity issues. Thus, given
the modes of action of DMPTA and Actinomycin-D (ActD), Lamture et al. [229] postulated that
combining both drugs would result in synergistic inhibition of Panc-1 pancreatic cancer cell growth,
since the inhibitory activity of DMAPT on FkB would enhance apoptosis induction by ActD, through
phosphorylation of c-Jun. Indeed, the combination of these two drugs produced a higher cell-death
percentage than each drug alone.
2.9. Thapsigargin
In 1978, the structure of thapsigargin (13) (C34H50O12) (Figure 10) was elucidated [230] for the
first time. It was found as the main component of Thapsia garganica L. [230,231], an umbelliferous
Apiaceae species distributed in the Mediterranean area. This plant has long been used in folk medicine
for treating common lung diseases (acute bronchitis and pneumonia) and dental pains [232]. The resin
from Thapsia garganica root was described in the French Pharmacopoeia [232].
Thapsigargin (13) yield ranged between 0.2–4.91% of the dry weight of leaves and roots
of Thapsia garganica and depends on the plant tissue, collection site (locality) and extraction
methods [231,233]. For example, classical maceration was more efficient than other methods such as
microwave-assisted extraction or simple extraction with liquid nitrogen [233].
Due to the importance of thapsigargin’s biological activities, there is great interest in its synthetic
and semi-synthetic preparation, thus several studies have been published on this subject [234,235].
Thapsigargin (13) is an inhibitor of the sarco/endoplasmic reticulum (ER) calcium ATPase (SERCA)
pump. The blockage of the SERCA pump results in malfunction of cellular calcium homeostasis
and exerts a critical role in normal cell metabolism, leading to apoptosis [236,237]. Moreover, this
sesquiterpene lactone causes apoptosis at all stages of the cell cycle.
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Compound 13 strongly inhibited all the subtypes of SERCA. The inhibitory constants (Ki) of
thapsigargin (13) were 0.21, 1.3, and 12 nm for SERCA1b, SERCA2b, and SERCA3a, respectively [238,239].
Its affini y with the SERCA1a pump is sig ificantly reduced by removal of the acyl groups at O-3, O-8
and O-10 [240].
Thapsigargin (13) p ssesses interesting pharmacological properties; for instance, it induces expression
of the L-histidine deca boxylase enzyme responsible for converting L-histidine to histamine in cells [241].
It also evokes ROS generation in cells through calcium-ion mediated changes (mitochondrial
depolarization), which can result in cell dysfunction and damage [242,243]. In addition, compound
13 is known for ts cytotoxic action against different cancer e l-lines, for instance melanoma [244],
insulinoma [245,246], neuronal [247], and breast [248].
The thapsigargin LD100 value is 0.8 mg/kg in mice [249]. Zhong et al. [250] proposed that
thapsigargin causes vomiting by tr ggeri g the phosphorylatio of CaMKIIα (Ca2+/calmoduli
kinase IIα) and ERK1/2 (extracellular ignal-regulated protein k nas 1/2) cascade in the b ainstem.
Pharmacological preconditioning with the cell-stress inducer thapsigargin (0.3 mg/kg) protects against
experim ntal sepsis in male KM (Kunming) mice [237].
Th ps gargin (13) is widely used as an experimental tool for endoplasmic reticulum stre s
inhibition and the discovery of new active therapeutic d rivat ve [232,251]. A n w thapsigargin (13)
derivative named mipsagargin, (8-O-(12-aminododecanoyl)-8-O-debutanoyl thapsigargin)-Asp-γ-Glu-
γ-Glu-γ-GluGluOH (14) (Figure 10), has been developed for anticancer therapy, notably for the
treatment of p ostate cancer. Mipsagargin (14) has the ability t link the C-8 with prostate-specific
membra e antig n (PSMA) peptide. It is a b nd new exampl of a thapsigargin prodrug, which
is currently und rgoing preclinical evaluation as a targeted chemotherapeutic agent with selective
toxicity against cancer cells [232,249]. Mahalingam and c authors reported that mi sagargin (14) has
an cceptable harmacokin tic profile in patients with solid tumors [252]. It is relatively well tolerated,
pro oting prolonged disease stabiliza ion in patie ts with advanced liver cancer [253].
2.10. Tomentosin
Tomentosin (15) (Figure 11), kn wn also as xa thalongin, is a xanthanolide sesquiterpene lactone
with the same chemical f rmula as inuviscolide (6) a d parthenolide (10) (C15H20O3). It has been
isolated from plants such as Dittrichia viscosa (L.) Greuter, Carpesium faberi C. Winkl. and Carpesium
macrocephalum Franch. and Sav. [254], Leucophyta brownii Cass. [255], the sunflower (Helianthus annuus
L.) [256] and Inula species [254,257]. Inula viscosa was widely used as a medicinal plant. A steam distilled
extract of its leaves and flowers yielding 2% of tomentosin (15) [258] exhibited anti-inflammatory,
antibacterial, and anticancer activities [257].
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The biological activities of to entosin (15) have been addressed in several studies focused on
anticancer, antifungal, and insecticidal activities.
Anticancer activity observed in vitro tests was confirmed by in vitro and in vivo studies performed
by Bar-Shalom et al. [259]. The authors found that application of an aqueous extract of Inula viscosa
leaves at a concentration of 300 µg/mL to colorectal cancer cells induced apoptosis, through activation
of caspases. During the subsequent in vivo study, mice transplanted with MC38 cells were treated
intraperitoneally with the extract at concentrations of 150 and 300 mg/kg. The results indicated that
tumor weight and volume were reduced significantly by this treatment after comparison with the
untreated control group. Furthermore, staining the paraffin section of the tumors showed inhibition
of cell proliferation, as well as induction of apoptosis. Interestingly, side effects, which often include
weight loss, impact on fur, and changes in behavior or kidney or liver functions, were not observed.
This suggests that the extract was non-toxic at the concentrations applied. However, this remains to be
confirmed [259].
Fungal infection of grapevines causes severe econo ic da age to grape producers. s several
fungicide-resistant strains of the pathogens have developed, efective fungicide application is becoming
more and more difficult. Therefore, natural products such as sesquiterpene lactones and plant extracts
may provide alternatives to current synthetic fungicides. The antifungal activity of six Inula viscosa
leaf extracts on downy mildew under field conditions was addressed in the study performed by
Cohen et al. [260]. This mildew is caused by the fungus Plasmopara viticola (Berk. and Curt.). The results
established that the effective concentration of oily paste extract in water required to control 90% of
the treated shoots in the field was lower than 0.125%. For whole vines, the required concentration
ranged between 0.30% and 0.37%. Additionally, the results did not appear to depend on seasonal
fluctuations. The evaluated leaf extracts contained 10.6% of tomentosin (15) and 10.6% of costic acid,
which were identified as the active principles with antifungal activity. The overall results indicated
that Inula viscosa extracts can be of great value as an alternative source for non-synthetic fungicidal
preparations to treat downy mildew infestations of grapes [260].
In an in vivo investigation perfor ed by Ahern et al. [261] on insecticidal activity, the effect
of the stereochemistry of the lactone ring on feeding behavior of the herbivorous polyphagous
grasshopper Schistocerca a ericana ( rury) as addressed. Schistocerca americana is locally related
in the south of the U.S. to significant damage to crops when temporary mass populations occur.
To evaluate the antifeedant activity of diastereomeric sesquiterpene lactones, the study focused
on tomentosin (15) with a cis-configuration and the corresponding iso er xanthinosin ith a
trans-configuration. The results showed both compounds were able to reduce plant consumption
by the insects. However, the trans-fused compounds were consumed less than the corresponding
cis-fused compounds. The results of this study not only permitted conclusions on the importance
of the stereochemistry-dependence of diastereomeric sesquiterpene lactones for insecticidal activity,
but also might help to understand the geographical distribution and evolution of different clades
among the Asteraceae family. The distribution of cis- and trans-fused compounds within plants of this
family is still not fully un erstood, in this study, 12.5% of the sampled Asteraceae genera contained
only cis-fused sesquiterpene lactones, 64% only trans-fused sesquiterpene lactones, and 23% both
types [261].
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3. Conclusions
Taking into account the research described above, the sesquiterpene lactones dealt with in this
review have proved to be very useful compounds with promising anticancer and anti-inflammatory
bioactivities in particular. For instance, alantolactone (1) was shown in vivo to be able to reduce tumor
size by over 50%, while increasing life expectancy and reducing pathological indicators across several
different cancer types. In addition, synergistic effects with well-known cancer therapeutics were also
reported. Arglabin (2) in salt form could be used to treat several cancers and possesses valuable
pharmacokinetic characteristics highly sought for in therapeutic drugs. It has no adverse effects
described in the literature. Antitrypanosomal, antitumor and anti-inflammatory activities are reported
for cynaropicrin (4). Another compound, helenalin (5), inhibits essential factors in both cancer and
inflammation, i.e., the NF-κB pathway and the transcription of inflammatory cytokines. Inuviscolide
(6) demonstrates potential as an anti-inflammatory therapeutic compound, being able to reduce rat ear
and paw edema and LTB4 generation in intact cells. Lactucin (7) and derivatives lactupicrin (8) and
lactucopicrin (9) have a strong potential as phytopharmaceutical agents for treatment of anxiety and
sleep disorders, being the main active components of long commercialized substances, e.g., Sedan®,
without observing side-effects.
Of all the sesquiterpene lactones reviewed in this work, parthenolide (10) and its derivatives
DMAPT (11) and HMPPPT (12) are those most mentioned in the literature, with several studies
particularly reporting their excellent anti-inflammatory and antitumor activities. Some work reveals
synergistic effects of these compounds with current anticancer drugs, favoring more potent and
selective antitumor action. Parthenolide derivatives have been designed and DMAPT (11) is 1000-fold
more soluble in water than the natural product, while maintaining a similar mechanism of action with
improved anticancer and anti-inflammatory activities.
Thapsigargin (13) has the particular capacity to cause endoplasmic reticulum stress and thus cell
apoptosis, an interesting pharmacological property to be retained or potentiated in derivatives aimed
at anticancer therapy. An example is mipsagargin (14), which is currently undergoing preclinical
evaluation for selective toxicity against cancer cells in tumor sites, with minimal side-effects for the
host. Another active compound is tomentosin (15), additionally with potential applications in cancer
but also as antifungal and antifeedant.
In summary, given the activities described in this review these sesquiterpene lactones exhibit
properties that justify more research by the scientific community, to drive preclinical and clinical
studies leading to development of new drugs.
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